PROTACs in the Management of Prostate Cancer

PROTACs in the Management of Prostate Cancer

Cancer treatments with targeted therapy have gained immense interest due to their low levels of toxicity and high selectivity. Proteolysis-Targeting Chimeras (PROTACs) have drawn special attention in the development of cancer therapeutics owing to their unique mechanism of action, their ability to t...

Full description

Bibliographic Details
Main Authors:	Poornachandra Yedla, Ahmed O. Babalghith, Vindhya Vasini Andra, Riyaz Syed
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Series:	Molecules
Subjects:	PROTAC prostate cancer androgen receptor mutation resistance
Online Access:	https://www.mdpi.com/1420-3049/28/9/3698

Similar Items

Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
by: Ga Yeong Kim, et al.
Published: (2021-04-01)

Targeting androgen receptor degradation with PROTACs from bench to bedside
by: Xiaojuan Jia, et al.
Published: (2023-02-01)

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy
by: Bohan Ma, et al.
Published: (2022-10-01)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
by: Arvind Negi, et al.
Published: (2022-11-01)

Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
by: Jian Huang, et al.
Published: (2022-03-01)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
by: Sinan Ma, et al.
Published: (2022-07-01)

Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
by: Qiao-Hong Chen, et al.
Published: (2024-02-01)

Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
by: Li Liu, et al.
Published: (2022-03-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?
by: Emre Yekedüz, et al.
Published: (2021-03-01)

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
by: Liang Jiang, et al.
Published: (2021-05-01)

Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants
by: Demitria M. Vasilatis, et al.
Published: (2023-04-01)

Photocontrollable PROTAC molecules: Structure and mechanism of action
by: Koravović Mladen, et al.
Published: (2021-01-01)

PROTACs: Walking through hematological malignancies
by: Lara J. Bou Malhab, et al.
Published: (2023-02-01)

The role of cyclins in the development and progression of prostate cancer
by: Joanna Dulińska-Litewka, et al.
Published: (2022-11-01)

Tubulin Resists Degradation by Cereblon-Recruiting PROTACs
by: Ivana Gasic, et al.
Published: (2020-04-01)

PROTACs targeting epigenetic proteins
by: Chao Zhang, et al.
Published: (2023-12-01)

Clinical relevance of androgen receptor alterations in prostate cancer
by: Emma Jernberg, et al.
Published: (2017-10-01)

Regulation of androgen receptor variants in prostate cancer
by: Yezi Zhu, et al.
Published: (2020-07-01)

The role of 11-oxygenated androgens in prostate cancer
by: Gido Snaterse, et al.
Published: (2023-04-01)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
by: Crowley F, et al.
Published: (2021-06-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
by: Nada Lallous, et al.
Published: (2021-06-01)

Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications
by: Arvind Negi, et al.
Published: (2022-09-01)

Clinical considerations for the design of PROTACs in cancer
by: Cristina Nieto-Jiménez, et al.
Published: (2022-03-01)

Recent Advances in Optically Controlled PROTAC
by: Muzi Ouyang, et al.
Published: (2023-11-01)

Antiviral PROTACs: Opportunity borne with challenge
by: Jinsen Liang, et al.
Published: (2023-06-01)

First small-molecule PROTACs for G protein-coupled receptors: inducing α1A-adrenergic receptor degradation
by: Zhenzhen Li, et al.
Published: (2020-09-01)

Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope
by: Sirin Saranyutanon, et al.
Published: (2019-12-01)

FOXA1 in prostate cancer
by: Hui-Yu Dong, et al.
Published: (2023-01-01)

PROTACs: The Future of Leukemia Therapeutics
by: Zubair Anwar, et al.
Published: (2022-09-01)

Stromal Androgen Receptor in Prostate Cancer Development and Progression
by: Damien A. Leach, et al.
Published: (2017-01-01)

Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?
by: Javier Pozas, et al.
Published: (2022-12-01)

Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
by: Mauro Scaravilli, et al.
Published: (2021-02-01)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
by: Alberto Ocaña, et al.
Published: (2020-09-01)

Endocrine Disruptors and Prostate Cancer
by: Margherita Corti, et al.
Published: (2022-01-01)

Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2021-03-01)

PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
by: Xuelian Liu, et al.
Published: (2023-01-01)

Androgen Receptor Roles in Benign and Malignant Prostate Disease
Published: (2011-06-01)

Application of PROTACs in target identification and validation
by: Yang Liu, et al.
Published: (2024-03-01)